Spark Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Spark Investment Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-12,837	Closed	-$70K	–	816
2019 Q1	$70K	Sell	12,837 -49,326	-79%	-$227K	﹤0.01%	596
2018 Q4	$188K	Sell	62,163 -27,429	-31%	-$95.1K	0.01%	504
2018 Q3	$375K	Buy	89,592 +12,254	+16%	+$51.6K	0.02%	493
2018 Q2	$298K	Buy	77,338 +2,730	+4%	+$18.1K	0.02%	503
2018 Q1	$472K	Buy	74,608 +61,008	+449%	+$505K	0.03%	407
2017 Q4	$109K	Buy	+13,600	New	+$127K	0.01%	616
2016 Q1	–	Sell	-12,634	Closed	-$785K	–	905
2015 Q4	$785K	Buy	+12,634	New	+$889K	0.1%	280
2015 Q3	–	Sell	-2,504	Closed	-$243K	–	815
2015 Q2	$243K	Sell	2,504 -27,250	-92%	-$2.59M	0.03%	490
2015 Q1	$2.78M	Buy	29,754 +6,291	+27%	+$535K	0.39%	63
2014 Q4	$2.09M	Buy	23,463 +11,960	+104%	+$871K	0.35%	81
2014 Q3	$793K	Buy	+11,503	New	+$615K	0.12%	251

Other funds holding MACK

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Spark Investment Management's MACK Position: Q2 2019 in Review

Spark Investment Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2019, closing a stake of 12,837 shares — an estimated $70K sold.

Spark Investment Management first reported a position in MACK in Q3 2014 and held it in 11 quarters. The position peaked at $2.78M in Q1 2015. 50 funds tracked by Wall St. Rank hold MACK as of Q2 2019.

Spark Investment Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Spark Investment Management sold 12,837 Merrimack Pharmaceuticals, Inc. shares in Q2 2019, an estimated $70K.
Spark Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 11 quarters.
Spark Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $2.78M in Q1 2015.
50 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2019.

Based on Spark Investment Management's 13F filing for Q2 2019, filed 12 Aug 2019.